Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olmesartan Medoxomil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 13/20 | 1.00 |
| ▸ | AGTR2 | P50052 | 12/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olmesartan Medoxomil SCHEMBL28341316 | 1.00 | AGTR1 (1.00) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL29087653 | 1.00 | AGTR1 (1.00) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL27822335 | 0.99 | AGTR1 (0.99) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL27934840 | 0.99 | AGTR1 (0.99) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL4132257 | 0.99 | AGTR1 (0.99) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL28547990 | 0.99 | AGTR1 (0.99) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL28754180 | 0.99 | AGTR1 (0.99) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL28754188 | 0.99 | AGTR1 (0.97) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL28754174 | 0.99 | AGTR1 (0.97) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| Olmesartan Medoxomil SCHEMBL29067178 | 0.97 | AGTR1 (0.95) | AGTR1AGTR2ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 20551 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747238-A1 | PROCESS FOR PREPARING INTERMEDIATES OF SARTAN ACTIVE COMPOUNDS | Sanofi (FR) | 2026-05-27 | — | — | EP | claimed |
| CN-121015662-B | Olmesartan medoxomil amlodipine hydrochlorothiazide three-compound preparation and preparation method and application thereof | 上海腾瑞制药股份有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260083726-A1 | COMPOSITIONS, SYSTEMS, AND METHODS FOR TREATING CANCER USING TUMOR TREATING FIELDS, CHEMOTHERAPEUTIC AGENTS, AND ANTI-FIBROTIC AGENTS | NOVOCURE GMBH (CH) | 2026-03-26 | — | — | US | claimed |
| EP-4215194-B1 | COMBINATION THERAPY OF AT1 R BLOCKER AND CCR2 INHIBITOR FOR THE TREATMENT, AMELIORATION OR PREVENTION OF A KIDNEY DISEASE | DIMERIX BIOSCIENCE PTY LTD (AU) | 2026-03-25 | — | — | EP | claimed |
| US-12582601-B2 | Orodispersible powder composition | BIOPHARMA SYNERGIES, S.L. (ES) | 2026-03-24 | — | — | US | claimed |
| EP-4709364-A1 | THERAPEUTIC FORMULATIONS FOR KIDNEY DISEASE COMPRISING REPAGERMANIUM OR PROPAGERMANIUM AND/OR AT1R BLOCKERS | Dimerix Bioscience Pty Ltd (AU) | 2026-03-18 | — | — | EP | claimed |
| EP-1258258-A1 | Implantable device comprising a stent and angiotensin II receptor antagonists | TERUMO KABUSHIKI KAISHA (JP) | 2002-11-20 | — | — | EP | claimed |
| US-20020168393-A1 | Implantable medical material and implantable medical device | TERUMO KABUSHIKI KAISHA (JP) | 2002-11-14 | — | — | US | claimed |
| WO-2002079778-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC. (US) | 2002-10-10 | — | — | WO | claimed |
| WO-2002043806-A2 | IN VIVO DELIVERY METHODS AND COMPOSITIONS | RHEOLOGICS, INC (US) | 2002-06-06 | — | — | WO | claimed |
| US-20020061835-A1 | Administering a drug to a human which is pharmaceutically effective to regulate at least one of the blood parameters used to adjust distribution of the drug through the bloodstream | RHEOLOGICS, INC. | 2002-05-23 | — | — | US | claimed |
| EP-1197226-A1 | PREVENTIVES FOR THE RECURRENCE OF CEREBROVASCULAR FAILURE AND AGENTS FOR AMELIORATING TROUBLES FOLLOWING CEREBROVASCULAR FAILURE AND INHIBITING PROGRESS THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-04-17 | — | — | EP | claimed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | claimed |
| WO-2002015933-A2 | COMBINATION COMPRISING AN AT1-RECEPTOR ANTAGONIST AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITISER | NOVARTIS AG (CH) | 2002-02-28 | — | — | WO | claimed |
| WO-2002015891-A2 | PHARMACEUTICAL COMBINATION OF ANGIOTENSIN II ANTAGONISTS AND ACE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-02-28 | — | — | WO | claimed |
| US-20010044584-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2001-11-22 | — | — | US | claimed |